RT Journal Article
SR Electronic
T1 Severe COVID-19 infection is associated with increased antibody-mediated platelet apoptosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187286
DO 10.1101/2020.09.03.20187286
A1 Althaus, Karina
A1 Marini, Irene
A1 Zlamal, Jan
A1 Pelzl, Lisann
A1 Häberle, Helene
A1 Mehrländer, Martin
A1 Hammer, Stefanie
A1 Schulze, Harald
A1 Bitzer, Michael
A1 Malek, Nisar
A1 Rath, Dominik
A1 Bösmüller, Hans
A1 Nieswandt, Bernard
A1 Gawaz, Meinrad
A1 Bakchoul, Tamam
A1 Rosenberger, Peter
YR 2020
UL http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187286.abstract
AB The pathophysiology of COVID-19 associated thrombosis seems to be multifactorial, involving interplay between cellular and plasmatic elements of the hemostasis. We hypothesized that COVID-19 is accompanied by platelet apoptosis with subsequent alteration of the coagulation system. We investigated depolarization of mitochondrial inner transmembrane potential (ΔΨm), cytosolic calcium (Ca2+) concentration, and phosphatidylserine (PS) externalization by flow cytometry. Platelets from intensive care unit (ICU) COVID-19 patients (n=21) showed higher ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization, compared to healthy controls (n=18) and COVID-19 non-ICU patients (n=4). Moreover significant higher cytosolic Ca2+ concentration and PS was observed compared to septic ICU control group (ICU control). In ICU control group (n=5; ICU non-COVID-19) cytosolic Ca2+ concentration and PS externalization was comparable to healthy control, with an increase ΔΨm depolarization. Sera from ICU COVID-19 13 patients induced significant increase in apoptosis markers (ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization). compared to healthy volunteer and septic ICU control. Interestingly, immunoglobulin G (IgG) fractions from COVID-19 patients induced an Fc gamma receptor IIA dependent platelet apoptosis (ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization). Enhanced PS externalization in platelets from ICU COVID-19 patients was associated with increased sequential organ failure assessment (SOFA) score (r=0.5635) and DDimer (r=0.4473). Most importantly, patients with thrombosis had significantly higher PS externalization compared to those without. The strong correlations between apoptosis markers and increased D-Dimer levels as well as the incidence of thrombosis may indicate that antibody-mediated platelet apoptosis potentially contributes to sustained increased thromboembolic risk in ICU COVID-19 patients.Key pointsSevere COVID-19 is associated with increased antibody-mediated platelet apoptosis.Platelet apoptosis in severe COVID-19 is correlated with D-Dimer and higher incidence of thromboembolisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the German Research Foundation and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study), DFG CRC/TR 240 Platelets-Molecular, cellular and systemic functions in health and disease (Project # 374031971) TP A03 (to H.S.), TP B01 (to M.G.), TP B07 (to P.R. and B.N.) and TUEFF-Gleichstellungsfoerderung to K.A. (2563-0-0)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all volunteers prior to any study-related procedure. All tests were performed with rest material from routine testing. The study protocol of patient material was approved by the Institutional Review Board of the University of Tuebingen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be requested for academic collaboration from the corresponding author.